Primary hyperaldosteronism is a well-established cause of secondary hypertension. 1 However, its importance in patients considered to have "primary" or "essential" arterial hypertension" is still under debate. 2 Vasan et al. using data from the Framingham cohort showed that normotensive subjects in the highest vs. the lowest quartile of aldosterone levels are at elevated risk of developing arterial hypertension in the future. 3 In the Framingham study, aldosterone levels were measured in samples drawn after the subject had been in a recumbent position for 5-10 minutes. We have previously shown that normotensive subjects with a positive family history of primary hypertension are characterized by inadequate suppression of aldosterone production during salt loading and prolonged aldosterone secretion in response to angiotensin II (Ang II) infusion. 4 Thus, in addition to increased resting levels of aldosterone, alterations in the dynamic regulation of aldosterone might be another, and less well studied, biochemical phenotype related to the future development of arterial hypertension.
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Head-up tilt testing is a widely established technique to investigate the effects of orthostatic stress on the cardiovascular system (particularly useful in the diagnostic work-up of patients with orthostatic hypotension or syncope). Because orthostatic stress is a more natural stimulus for the release of aldosterone compared with Ang II infusion, we have utilized this method in the current study to investigate the effect of orthostatic stress on blood pressure (BP) regulation and hormonal response in young patients with early arterial hypertension. The hypothesis was that patients with early arterial hypertension may already demonstrate an exaggerated release of aldosterone during stimulation by orthostatic stress.
METHODS

Study population
Study subjects were consecutively enrolled to recruit 45 normotensive and 45 hypertensive otherwise healthy, male subjects. Hypertension was defined as office BP greater or equal to 140/90 mm Hg on at least 2 occasions. All individuals were subjected to a thorough work-up to exclude secondary causes of hypertension including renal artery stenosis and primary hyperaldosteronism, and to further exclude hypertensive target-organ damage (including left ventricular hypertrophy and microalbuminuria or macroalbuminuria). Before enrolment in the study, written informed consent was obtained from each participant. The study protocol was approved by the institutional review board of the University of Erlangen-Nürnberg. The study was performed in adherence to the principles of the Declaration of Helsinki and according to GCP standards. The study was registered with ClinicalTrials.gov (NCT00865501).
BP measurement
For office BP, a standardized sphygmomanometer was used with the cuff size adjusted to the subjects arm circumference. After the patient had been seated for 5 minutes, office BP was determined as the mean of 3 consecutive measurements.
24-hour urine collection
Urine was collected over 24 hours the day before the head-up tilt to estimate dietary sodium intake. 5, 6 Urine samples containing less than 15 mg/kg body weight of creatinine over 24 hours (n = 7) were excluded due to assumed collecting error.
Head-up-tilt testing
The design of the head-up tilt testing study is shown in Figure 1 . After a light breakfast the patients were brought in the supine position. After 30 minutes of rest, baseline recording of hemodynamic parameters was performed for 30 minutes. Then head-up-tilting was performed at an angle of 75° for 30 minutes. Along with the continued hemodynamic measurements, blood samples were drawn for the measurement of hormone levels after 0, 5, 10, 15, and 30 minutes of tilting.
Hemodynamic parameters
Hemodynamic parameters were measured the TaskForce Monitor device (CNSystems, Graz, Austria). BP was measured beat-to-beat by a finger device calibrated by a conventional oscillometric measurement on the arm. Systolic, diastolic, and mean arterial pressure were derived from the BP curve of the finger. Heart rate (HR) was measured by electrocardiography, stroke volume by impedance cardiography. Cardiac output (cardiac output = stroke volume * HR) was then used to calculate cardiac index (CI) as CI = cardiac output/body surface area and total peripheral vascular resistance index (TPRI) as (mean arterial pressure − 3) * 80/ cardiac output/body surface area.
Aldosterone, Ang II, and plasma renin activity Serum aldosterone levels were measured by a commercially available test kit (Aldosterone MAIA, BioChem ImmunoSystems, Bologna, Italy). The limit of detection of this assay is 6.0 pg/ml. Interassay variance is 6.4 % and intra-assay variance is 5.4 %. Blood samples for the determination of plasma Ang II and plasma renin activity (PRA) were collected in prechilled syringes containing enzyme inhibitors. The samples were centrifuged for 10 minutes at 4 °C immediately after collection, and plasma was stored rapidly after centrifugation at −21 °C and analyzed within 3 months. Peptides were extracted from plasma with Bond Elut PH cartridges (PK 100, ICT-ASS-Chem). Ang II was measured by radioimmunoassay. Cross-reactivity was 1.2% for Ang I and 100% for Ang III and Ang IV, respectively. All measurements were done in duplicate, and the mean value is given. The coefficient of variation was 8.8%. PRA was measured by angiotensin I radioimmunoassay.
Statistical analysis
Statistical analyses were performed using SPSS software package (SPSS for Windows 22.0, SPSS, Chicago, IL) and GraphPad Prism version 6 (GraphPad Software, La Jolla, CA). Two-way analysis of variance was used to assess the effects of group (hypertensive vs. normotensive), time after tilting, and their interaction (group * time) on the response of mean arterial pressure, HR, CI, TPRI, PRA, Ang II, and aldosterone during head-up tilt. Linear regression analysis was performed to assess the effects of explanatory variables on the increase of aldosterone at 30 minutes after tilting. Variables were entered simultaneously into the model. The level of significance was set to P <0.05 (2-tailed). All values are given as mean ± SD unless noted otherwise.
RESULTS
Clinical characteristics
Clinical characteristics of all subjects enrolled are shown in Table 1 . In addition to greater office and 24-hour BP values, hypertensive subjects had slightly greater BMI and Figure 1 . Design of the head-up tilt testing study.
higher 24-hour urinary sodium excretion compared with normotensive subjects.
Hemodynamic parameters during head-up tilt
The timeline of head-up tilt testing is shown in Figure 1 . After a 30-minute rest period, baseline hemodynamic data was recorded at intervals for 30 minutes. Then, subjects were brought into head-up tilt position (75°), and hemodynamics were again recorded at intervals (0, 5, 10, 15, and 30 minutes after tilting). Figure 2 shows the hemodynamic response during head-up tilt at these time points. Mean arterial pressure and TPRI, which were higher in the hypertensive subjects, increased in both groups during head-up tilt. HR and CI were not different between groups, and increased during head-up tilt in both groups similarly. No interactions between group and time effects were found for these parameters.
Hormonal response during head-up tilt
Baseline measurements of the hormones were drawn after the 30 minutes of baseline recording of hemodynamics (time = 0 of tilting). There were no differences in PRA, Ang II, or aldosterone at time = 0 before head-up tilt (Table 2) .
PRA and Ang II increased during head-up tilt, but there was no interaction of this increase with hypertension status (Figure 3 ). Aldosterone also increased during head-up tilt. However, this increase was significantly greater in the hypertensive vs. the normotensive subjects (P = 0.0021 for interaction group * time).
Finally, linear regression analysis was performed to assess the potential contribution of covariates on aldosterone increase, particularly BMI and urinary sodium excretion, which differed between hypertensives and normotensives ( Table 1) . Hypertension status and urinary sodium excretion were identified as statistically significant explanatory variables of aldosterone increase at 30 minutes after tilt, while BMI failed to reach statistical significance (P = 0.070, Table 3 ). As expected, urinary sodium excretion was inversely related with aldosterone increase. Although not different between the hypertensive and normotensive groups, we also assess the role of family history of hypertension as a covariate. Family history of hypertension was found to be of borderline statistical significance as a covariate of aldosterone increase (P = 0.053).
DISCUSSION
Aldosterone has numerous genomic and nongenomic effects on the kidney, the vasculature, and the sympathetic nervous system that promote an increase of BP. Frank primary hyperaldosteronism due to adrenal adenoma or hyperplasia is a well-established cause of secondary hypertension. Further, the role of aldosterone in treatment resistant hypertension has been impressively demonstrated by the ASPIRANT and PATHWAY-2 studies. In ASPIRANT, spironolactone was significantly superior to placebo, and in PATHWAY-2, spironolactone superior compared with alphablockade or betablockade as regards achieving BP control in patients with treatment resistant arterial hypertension. 7, 8 Since data from the Framingham study showed that higher resting aldosterone levels within the normal range precede the development of arterial hypertension, aldosterone has also been considered as a driver for the development of "primary" or "essential" hypertension. 3 However, in keeping with its physiological functions, aldosterone levels are highly dynamic and measurements of resting aldosterone levels may not capture subjects with more subtle dysregulation of aldosterone release. Thus, in the current study, we examined aldosterone release in young patients with early arterial hypertension and normotensive control subjects. The key finding of the current study was that despite similar aldosterone levels at baseline, the increase of aldosterone during head-up tilt was increased in young patients with arterial hypertension compared with healthy control subjects. Thus, our findings would also be in line with a much wider role of aldosterone, extending its relevance to subjects with "primary" or "essential" hypertension.
Our study has several strengths and limitations. Strength of the current study is the careful characterization and phenotyping of the enrolled patients and controls. One limitation is the lack of information on the repeatability/ robustness of aldosterone release in response to tilt testing. Head-up tilt testing is commonly used in patients presenting with orthostatic hypotension or syncope. Concurrent assessment of hormonal responses has been shown to provide additional information that increases the diagnostic ability to define clinical subgroups. 9 However, future studies have to assess repeatability if this method becomes more widely used to complement head-up tilt testing in patients with syncope or hypertension. Another limitation is the relatively small sample size, a common issue of mechanistic studies.
We performed a linear regression analysis to study the role of covariates. In addition to hypertensive status, urinary sodium excretion, which reflects dietary salt intake under stable conditions, was found as a significant covariate of aldosterone release. As expected, the relationship between urinary sodium and aldosterone release was inverse, with greater urinary sodium excretion, i.e., greater dietary salt intake, being linked with suppressed release of aldosterone during tilt. BMI failed to reach statistical significance as an explanatory variable of aldosterone release (P = 0.070), but this may have been an issue of the relatively small sample size. Previous studies have found increased (resting) aldosterone levels in obese patients with arterial hypertension. 10 Human adipose tissue has been shown to contain all components necessary for generation of Ang II, which may explain at least in part why aldosterone levels were reported to be elevated in obese hypertensive subjects. 10 Adipose tissue releases additional secretagogues of aldosterone unrelated to the renin-angiotensin system, including fatty acids, endothelin-1, leptin, and complement-C1q TNF-related protein 1 (CTRP1). [11] [12] [13] [14] Interestingly, we did not find a difference in the increase of PRA or Ang II during tilt between hypertensives vs. normotensives, suggesting that the exaggerated aldosterone release in hypertensives may be due to stimulation by other secretagogues.
Finally, we have found positive family history of hypertension to be linked with aldosterone release during tilt (borderline significant at P = 0.053). There is in fact evidence that genes may play a role in the aldosterone release. On the one hand, there are rare monogenetic forms of arterial hypertension involving aldosterone action, including Liddle syndrome (caused by dysregulation of an epithelial sodium channel due to a genetic mutation) and glucocorticoid-remediable hypertension (autosomal dominant mutation resulting in hybrid gene of aldosterone synthase that is rendered ACTHsensitive). These monogenetic genetic forms provide proof of the overall prohypertensive effects of increased aldosterone action, but these forms of hyperaldosteronism are rare and variations at these gene loci (in the sense of common gene polymorphisms rather than rare mutations with large effects) do not seem to be relevant for most patients with "primary" or "essential" hypertension. The genetic contribution to "primary" hypertension is polygenic, and a variety of variants at gene loci resulting in small absolute effects on BP have been discovered through genome-wide association studies. For several years, the −344C/T gene polymorphism in the promotor region of aldosterone synthase has been the prime candidate as carrier of genetic risk for increased aldosterone production, higher BP, and more severe end-organ damage in "primary" hypertension. However, this gene polymorphism was not associated with BP phenotype in several genome-wide association studies, albeit that a role for left ventricular hypertrophy via modulation of local aldosterone levels cannot be ruled out. 15, 16 Interestingly, 2 other loci in steroid pathways leading to production of aldosterone have been associated with BP level more recently: the CYP17A1 gene locus encoding 17α-hydroxylase and the HSD3B1 gene locus encoding 3beta-hydroxysteroid dehydrogenase (the latter linked with BP response to diuretic therapy). 17, 18 Interestingly, 17α-hydroxylase is involved not only in the production of steroid hormones including aldosterone, but also in their metabolism. Thus, future studies should aim to relate variation at this locus with prolonged increases of aldosterone after stimulation, as observed in our previous study in subjects with a positive family history of hypertension. 4 In summary, we could demonstrate that young patients with early arterial hypertension are characterized by exaggerated aldosterone release during orthostatic stress. These data further promote the concept that dysregulation of aldosterone plays a much wider role in arterial hypertension, beyond its more established roles in secondary and treatment resistant hypertension. Early identification of subjects with dysregulation of aldosterone release, e.g., by tilt testing, may help to prevent the development of hypertension and related end-organ damage by targeted intervention.
